Interim biomarker results of trontinemab, a novel Brainshuttle TM antibody in development for the treatment of Alzheimer's disease
In addition to changes in amyloid PET, new results on relevant CSF and plasma downstream biomarkers showing a trend in the right direction and volumetric MRI results in line with the recent literature.
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.